Biofil Chemicals & Pharmaceuticals Ltd. (IN:BIOFILCHEM)
:BIOFILCHEM
BIOFILCHEM Stock Chart & Stats
₹33.59
-₹0.32(-0.55%)
At close: 4:00 PM EST
₹33.59
-₹0.32(-0.55%)
Day’s Range― - ―
52-Week Range₹27.30 - ₹56.36
Previous CloseN/A
Volume25.08K
Average Volume (3M)6.87K
Market Cap
₹456.15M
Enterprise Value₹449.13M
Total Cash (Recent Filing)₹3.59M
Total Debt (Recent Filing)₹200.00K
Price to Earnings (P/E)172.4
Beta1.30
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding16,273,800
10 Day Avg. Volume7,559
30 Day Avg. Volume6,869
Financial Highlights & Ratios
PEG Ratio-5.50
Price to Book (P/B)3.72
Price to Sales (P/S)2.09
P/FCF Ratio-34.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Healthy Balance Sheet / Manageable LeverageA strong equity ratio and moderate leverage give the company financial flexibility to absorb shocks, fund necessary investments, and access credit on reasonable terms. This capital structure supports stability and strategic optionality over the next several months.
Operational Efficiency With Positive EBIT/EBITDASustained positive operating margins point to effective cost control and core profitability. Even if revenue fluctuates, these margins help preserve operating cash flow potential and provide a durable earnings base once top-line pressures ease.
Position In Specialty & Generic Drug IndustryOperating in the specialty and generic drugs segment exposes the company to structural demand, regulatory barriers to entry, and recurring product needs. These industry characteristics support medium-term revenue stability and long-term demand resilience.
Bears Say
Significant Recent Revenue DeclineA steep year-over-year revenue decline reduces scale and pressures margin coverage of fixed costs. Persistent top-line contraction can erode market position, limit reinvestment capacity, and make recovery harder absent clear demand or commercial improvements.
Inconsistent Cash Generation And Negative FCF GrowthNegative free cash flow growth driven by elevated capex and uneven operating cash conversion raises liquidity risk. This constrains internal funding for growth, increases reliance on external financing, and reduces the margin for error during market stress.
Volatile Net ProfitabilityVariability in net margins undermines earnings predictability and retention of profits for reinvestment. Even with positive operating margins, bottom-line volatility can weaken credit metrics, complicate planning, and dampen investor confidence over the medium term.
Biofil Chemicals & Pharmaceuticals Ltd. News
BIOFILCHEM FAQ
What was Biofil Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
Biofil Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹27.30 and its highest was ₹56.36 in the past 12 months.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s market cap?
Biofil Chemicals & Pharmaceuticals Ltd.’s market cap is ₹456.15M.
When is Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 66 days.
How were Biofil Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
Biofil Chemicals & Pharmaceuticals Ltd. released its earnings results on Feb 13, 2026. The company reported ₹0.049 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.049.
Is Biofil Chemicals & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Biofil Chemicals & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Biofil Chemicals & Pharmaceuticals Ltd. pay dividends?
Biofil Chemicals & Pharmaceuticals Ltd. does not currently pay dividends.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biofil Chemicals & Pharmaceuticals Ltd. have?
Biofil Chemicals & Pharmaceuticals Ltd. has 16,273,800 shares outstanding.
What happened to Biofil Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
Biofil Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹0.049 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.921%.
Which hedge fund is a major shareholder of Biofil Chemicals & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:BIOFILCHEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofil Chemicals & Pharmaceuticals Ltd.
Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical and chemical businesses primarily in India. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and plastic dippers and caps. It also provides job work service for manufacturing of pharmaceuticals. The company was incorporated in 1985 and is based in Indore, India.
Technical Analysis
Bal Pharma Limited
―
―
Lasa Supergenerics Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Vaishali Pharma Ltd.
―